Merck & Co Inc
MRK
ISIN US58933Y1055 / Valor 10683053
Merck & Co Inc
UMushroom community rating:
About company
Merck & Co Inc, known outside the United States and Canada as Merck KGaA, Darmstadt, Germany, is a global science and technology company with a focus on healthcare, life sciences, and electronics. Founded in 1851, the company has established itself as a pioneer in the science and technology sector, aiming to leverage its expertise to address some of the world's most pressing challenges, including disease, poverty, hunger, and climate change. Merck & Co Inc is committed to driving innovation and growth through its "Mobilize for Growth" strategy, which seeks to unlock the company's full potential and achieve a target of approximately €25 billion in sales by 2025. A significant portion of this growth is expected to come from its three main business sectors: Process Solutions and Life Science Services within the Life Science sector, new Healthcare products, and Semiconductor Solutions within the Electronics sector. The company emphasizes the importance of quality, sustainability, and corporate responsibility in its operations, aiming to create value not only for its customers and patients but also for society at large.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (29.03.2025):
Revenue Growth
Merck & Co Inc reported a strong revenue growth for the fourth quarter of 2024, with total revenue reaching $15.6 billion. This reflects sustained demand for their innovative portfolio, including the successful launch of WINREVAIR and robust performance in their Animal Health business.
Full-Year Revenue
For the full year of 2024, Merck & Co Inc achieved total worldwide sales of $64.2 billion, marking a significant increase compared to previous years. This growth underscores the company's successful execution of its strategic initiatives and strong market presence.
Earnings Per Share
In the fourth quarter of 2024, Merck & Co Inc reported a GAAP earnings per share (EPS) of $1.48 and a non-GAAP EPS of $1.72. These figures include a charge of $0.23 per share related to certain business development transactions, highlighting the company's ongoing investment in growth opportunities.
Full-Year Earnings
For the full year of 2024, Merck & Co Inc's GAAP EPS was $6.74, while the non-GAAP EPS stood at $7.65. These results include a net charge of $1.28 per share from business development transactions, reflecting the company's strategic focus on expanding its pipeline and market reach.
2025 Financial Outlook
Looking ahead, Merck & Co Inc has provided a financial outlook for the full year of 2025, projecting worldwide sales between $64.1 billion and $65.6 billion. The non-GAAP EPS is expected to range from $8.88 to $9.03, factoring in a one-time charge of approximately $0.09 per share related to an anticipated milestone payment to LaNova.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
248840 M
Market cap (USD)
12,393,480
Daily traded volume (Shares)
99.38 / 98.28
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Claudia Stadelmann
Lou Charlotte Wehrli
EQUITIES OF THE SAME SECTOR
